Original language | English |
---|---|
Pages (from-to) | 843-844 |
Number of pages | 2 |
Journal | Journal of Neurology, Neurosurgery and Psychiatry |
Volume | 90 |
Issue number | 7 |
DOIs | |
State | Published - 1 Jul 2019 |
Keywords
- Parkinson's disease
- genetics
- movement disorders
- neurogenetics
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease. / Ortega, Roberto Angel; Groves, Mark; Mirelman, Anat et al.
In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, No. 7, 01.07.2019, p. 843-844.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease
AU - Ortega, Roberto Angel
AU - Groves, Mark
AU - Mirelman, Anat
AU - Alcalay, Roy N.
AU - Raymond, Deborah
AU - Elango, Sonya
AU - Mejia-Santana, Helen
AU - Giladi, Nir
AU - Marder, Karen
AU - Bressman, Susan B.
AU - Saunders-Pullman, Rachel
N1 - Funding Information: Funding This study was funded by the Michael J Fox Foundation for Parkinson’s research and the National Institute of Neurological Disorders and stroke (NINDs-K02Ns073836). Funding Information: Competing interests sBB and rs-P have received consulting fees from Denali Therapeutics Inc. rNA has received consulting fees from Denali, Biogen and Genzyme/sanofi. NG serves as a member of the Editorial Board for the Journal of Parkinson’s Disease. He serves as consultant to sionara, Accelmed, Teva, NeuroDerm, IntecPharma, Pharma2B, Denali and Abbvie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at Teva, UCB, Abbvie, sanofi-Genzyme, Bial and Movement Disorder society. NG received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program and the Israel science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer.
PY - 2019/7/1
Y1 - 2019/7/1
KW - Parkinson's disease
KW - genetics
KW - movement disorders
KW - neurogenetics
UR - http://www.scopus.com/inward/record.url?scp=85056418655&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2018-319364
DO - 10.1136/jnnp-2018-319364
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???
C2 - 30409888
AN - SCOPUS:85056418655
SN - 0022-3050
VL - 90
SP - 843
EP - 844
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 7
ER -